Colorectal disorders:

Indications for: LIALDA

For induction and maintenance of remission in adults with mildly to moderately active ulcerative colitis. To treat mildly to moderately active ulcerative colitis in pediatric patients weighing ≥24kg.

Adult Dosage:

Swallow whole with food. Induction: 2.4–4.8g once daily. Maintenance: 2.4g once daily.

Children Dosage:

<24kg: not established. Swallow whole with food. Take once daily. 24–35kg (Weeks 0 to 8): 2.4g; (after Week 8): 1.2g. >35–50kg (Weeks 0 to 8): 3.6g; (after Week 8): 2.4g. >50kg (Weeks 0 to 8): 4.8g; (after Week 8): 2.4g.

LIALDA Warnings/Precautions:

Sulfasalazine allergy. Upper GI tract obstruction (eg, pyloric stenosis) may delay onset of action. Discontinue if acute intolerance syndrome is suspected. Discontinue at the 1st signs/symptoms of severe cutaneous adverse reactions. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Nephrolithiasis. Ensure adequate hydration. Renal or hepatic impairment. Monitor renal function prior to and periodically during therapy. Elderly (monitor CBCs, platelets). Pregnancy. Nursing mothers: monitor infants.

LIALDA Classification:


LIALDA Interactions:

Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk for blood disorders, bone marrow failure, and associated complications with azathioprine or 6-mercaptopurine and/or other drugs known to cause myelotoxicity. May cause elevated test results when measuring urinary normetanephrine.

Adverse Reactions:

Headache, flatulence, abnormal LFTs, abdominal pain, diarrhea; children also: upper RTI, vomiting, anemia, viral infection; acute intolerance syndrome (cramping, bloody diarrhea, fever, headache, rash), renal impairment, hypersensitivity reactions, severe cutaneous adverse reactions (eg, SJS, TEN, DRESS, AGEP); rare: pancreatitis.

Generic Drug Availability:


How Supplied:


Pricing for LIALDA

1.2g tablet (Qty: 120)
Appx. price $282